Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 1-10 of 51

Page
per page
  1. Gefitinib (ZD1839)
    A8219 Gefitinib (ZD1839)
     3 Citation
    Target: EGFR
    Summary: Selective EGFR inhibitor
      ≥22.34 mg/mL
  2. Gemcitabine HCl
    A1402 Gemcitabine HCl
    Summary: Inhibits DNA synthesis,deoxycytidine analog
      ≥10.1 mg/mL
  3. SU11274
    A2678 SU11274
     2 Citation
    Target: MET
    Summary: C-Met inhibitor,potent and selective
      ≥28.4 mg/mL
  4. Masitinib (AB1010)
    A2942 Masitinib (AB1010)
    Target: PDGFR|c-Kit|Lyn
    Summary: Tyrosine kinase inhibitor, potent and selective
      ≥24.95 mg/mL
  5. Zoledronic Acid
    A1352 Zoledronic Acid
    Target: Farnesyl Diphosphate Synthases
    Summary: Potent nitrogen-containing bisphosphonates
      insoluble in DMSO; insoluble in H2O; insoluble in EtOH
  6. PHA-793887
    A5459 PHA-793887
     1 Citation
    Target: Cyclin-Dependent Kinases
    Summary: Pan-Cdk inhibitor
      insoluble in H2O; ≥18.05 mg/mL
  7. PF-562271
    A8310 PF-562271
     1 Citation
    Target: FAK|Pyk2
    Summary: ATP-competitive FAK inhibitor, reversible
      ≥25.35 mg/mL
  8. PD 0332991 (Palbociclib) HCl
    A8316 PD 0332991 (Palbociclib) HCl
     5 Citation
    Target: Cyclin-Dependent Kinases
    Summary: CDK4/6 inhibitor,highly selective
      ≥14.48 mg/mL
  9. PF-00562271
    A8320 PF-00562271
    Target: FAK|Pyk2
    Summary: FAK/Pyk2 inhibitor,potent and ATP-competitive
      insoluble in EtOH; insoluble in H2O; ≥11.1 mg/mL
  10. Tivantinib (ARQ 197)
    A8325 Tivantinib (ARQ 197)
     2 Citation
    Target: MET
    Summary: C-Met inhibitor,non-ATP-competitive
      ≥18.47 mg/mL

Items 1-10 of 51

Page
per page